Nanopharm & Fluidda Discuss FDA’s New Inhaled Product Guidelines
Explore how alternative bioequivalence methods, including computational fluid dynamics and in silico modeling, are shaping the future of generic drug approval.
Interview with Rob Bootle: Advancements in Nanopharm’s OINDPs
Join Rob Bootle as he explores his journey at Nanopharm, highlighting the company’s cutting-edge research and development in orally inhaled and nasal drug products (OINDPs).
Accelerate DPI Clinical Success with Innovative De-Risking Strategy
Discover the comprehensive session of ‘Empowering the Path to Clinical: Innovative Strategies for De-Risking DPI Product Development’ from RDD 2024.
Optimising batch selection to increase success of PK studies for bioequivalence
Uncover Nanopharm’s SmartTrack approach for successful Pharmacokinetic and Bioequivalence studies in OINDP, using PBPK modelling.
Alternative Regulatory Pathway for Generic Inhaled Drugs
Uncover the pathways for generic OINDP and the challenges and solutions in the pharmaceutical regulatory landscape for inhalation drug products.
Why it is time to ‘Think Different’ about nasal delivery of biologics.
Nanopharm discusses the challenges and benefits of delivering biologics via the nasal route.
Nanopharm’s Role in OINDP Bioequivalence & Pharmacokinetics
Explore Nanopharm’s groundbreaking methods in OINDP bioequivalence and pharmacokinetics. Learn how in vitro and in vivo studies are revolutionizing drug development and solubility.
Nasal Drug Development, Trends and Challenges with Nasal Formulations
Nanopharm explores the current trends and technical challenges in nasal drug product development, focusing on formulation.
Nanopharm’s Innovations in Nasal Drug Delivery of Biologics
Discover Nanopharm’s pioneering work in nasal drug delivery of biologics. Learn how their research is shaping drug development against SARS-CoV-2.
Investigating The Propellant Pathways Leading To a Sustainable Future of MDIs
Download the Article Description: The article discusses the transition to low GWP propellants in the respiratory drug delivery sector as current high-GWP variants are phased out. The leading propellant options for the next generation of low GWP MDIs ( metered dose inhalers) are HFA 152a and HFO 1234ze from the hydro-fluoroolefin family. The article highlights […]
